ECSP034595A - ALFA ACTIVATED RECEPTOR AGONIST OF THE PEROXISOM PROLIFER - Google Patents
ALFA ACTIVATED RECEPTOR AGONIST OF THE PEROXISOM PROLIFERInfo
- Publication number
- ECSP034595A ECSP034595A EC2003004595A ECSP034595A ECSP034595A EC SP034595 A ECSP034595 A EC SP034595A EC 2003004595 A EC2003004595 A EC 2003004595A EC SP034595 A ECSP034595 A EC SP034595A EC SP034595 A ECSP034595 A EC SP034595A
- Authority
- EC
- Ecuador
- Prior art keywords
- group
- substituted
- alkyl
- unsubstituted
- hydrogen
- Prior art date
Links
- 210000002824 peroxisome Anatomy 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000005466 alkylenyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 229940124530 sulfonamide Drugs 0.000 abstract 2
- 150000003456 sulfonamides Chemical class 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000005001 aminoaryl group Chemical group 0.000 abstract 1
- -1 and R4 is H Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000005002 aryl methyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000003857 carboxamides Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 150000003536 tetrazoles Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/22—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having nitrogen atoms of amidino groups further bound to nitrogen atoms, e.g. hydrazidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/02—Compounds containing any of the groups, e.g. carbazates
- C07C281/04—Compounds containing any of the groups, e.g. carbazates the other nitrogen atom being further doubly-bound to a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cultivation Of Plants (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
(c) R2 es Ho un grupo sustituido o insustituido seleccionado del grupo constituido por alquilo C1-C6, alilo C1-C6, arilalquilo Co-C4, heteroari-alquilo C0-C4, sulfonamida, amida, OR10 y cicloalquilo C3-C6; (d) X es un alquileno C1-C5 de unión opcionalmente sustituido en el que un átomo de carbono del elemento de unión puede estar sustituido con O, NH o S; (e) Y es C, O, S, NH o un enlace sencillo; y (f) E se selecciona del grupo constituido por hidrógeno, C (R3) (R4) A, A, sustituido o insustituido, seleccionado del grupo constituido por hidrógeno, C(R3) (R4) A, A, sustituido o insustituido , seleccionado del grupo constituido por (CH2)n COOR19, alquilo C1-C4, aminoarilo y aminoalquilo C1-C4 y en la que n es 0, 1, 2 o 3, A es un grupo funcional seleccionado del grupo constituido por carboxilo, alquilnitrilo C1-C3, carboxamida, sulfonamida sustituida o insustituida y tetrazol sustituido o insustituido; R3 es H, alquilo C1-C5 saturado o insaturado, alcoxi C1-C5, y R4 es H, halo, un grupo sustituido o insustituido seleccionado entre alquilo C1-C5, alcoxi C1-C5, cicloalquilo C3-C6, arilalquilo C0-C4 y fenilo o R3 y R4 se conbinan para formar un cicloalquilo C3-C4; R19 se selecciona del grupo constituido por hidrógeno, arilmetilo opcionalmente sustituido y alquilo C1-C4 opcionalmente sustituido; R8 se selecciona independientemente del grupo constituido por hidrógeno, alquilo C1-C4, alquilenilo C1-C4 y halo; R9 se selecciona independientemente del grupo constituido por hidrógeno, alquilo C1-C4, alquilenilo C1- C4, halo, arilo sustituido o insustituido, arilalquilo C1-C4 sustituido o insustituido, heteroarilo sustituido o insustituido, slilo V1-C6 y =R10; y R10 se selecciona independientemente del grupo constituido por hidrógeno y alquilo C1-C4.(c) R2 is Ho a substituted or unsubstituted group selected from the group consisting of C1-C6 alkyl, C1-C6 allyl, Co-C4 arylalkyl, C0-C4 heteroaryl-alkyl, sulfonamide, amide, OR10 and C3-C6 cycloalkyl; (d) X is an optionally substituted C1-C5 binding alkylene in which a carbon atom of the bonding element may be substituted with O, NH or S; (e) Y is C, O, S, NH or a single bond; and (f) E is selected from the group consisting of hydrogen, C (R3) (R4) A, A, substituted or unsubstituted, selected from the group consisting of hydrogen, C (R3) (R4) A, A, substituted or unsubstituted, selected from the group consisting of (CH2) n COOR19, C1-C4 alkyl, aminoaryl and C1-C4 aminoalkyl and wherein n is 0, 1, 2 or 3, A is a functional group selected from the group consisting of carboxyl, C1-alkylnitrile -C3, carboxamide, substituted or unsubstituted sulfonamide and substituted or unsubstituted tetrazole; R3 is H, C1-C5 alkyl saturated or unsaturated, C1-C5 alkoxy, and R4 is H, halo, a substituted or unsubstituted group selected from C1-C5 alkyl, C1-C5 alkoxy, C3-C6 cycloalkyl, C0-C4 arylalkyl and phenyl or R3 and R4 combine to form a C3-C4 cycloalkyl; R19 is selected from the group consisting of hydrogen, optionally substituted arylmethyl and optionally substituted C1-C4 alkyl; R8 is independently selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 alkylenyl and halo; R9 is independently selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 alkylenyl, halo, substituted or unsubstituted aryl, substituted or unsubstituted C1-C4 arylalkyl, substituted or unsubstituted heteroaryl, slile V1-C6 y = R10; and R10 is independently selected from the group consisting of hydrogen and C1-C4 alkyl.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24731700P | 2000-11-10 | 2000-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP034595A true ECSP034595A (en) | 2003-06-25 |
Family
ID=22934453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2003004595A ECSP034595A (en) | 2000-11-10 | 2003-05-08 | ALFA ACTIVATED RECEPTOR AGONIST OF THE PEROXISOM PROLIFER |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US7304062B2 (en) |
| EP (1) | EP1335908B1 (en) |
| JP (1) | JP4243101B2 (en) |
| KR (1) | KR100839705B1 (en) |
| CN (1) | CN1479728A (en) |
| AR (1) | AR031305A1 (en) |
| AT (1) | ATE386026T1 (en) |
| AU (3) | AU2002228592B8 (en) |
| BR (1) | BR0114986A (en) |
| CA (1) | CA2421154A1 (en) |
| CY (1) | CY1107388T1 (en) |
| CZ (1) | CZ20031283A3 (en) |
| DE (1) | DE60132799T2 (en) |
| DK (1) | DK1335908T3 (en) |
| EA (1) | EA006920B1 (en) |
| EC (1) | ECSP034595A (en) |
| ES (1) | ES2300378T3 (en) |
| HR (1) | HRP20030365A2 (en) |
| HU (1) | HUP0301655A2 (en) |
| IL (2) | IL154840A0 (en) |
| MX (1) | MXPA03004141A (en) |
| MY (1) | MY157884A (en) |
| NO (1) | NO20032059L (en) |
| NZ (1) | NZ524569A (en) |
| PE (1) | PE20020693A1 (en) |
| PL (1) | PL362692A1 (en) |
| PT (1) | PT1335908E (en) |
| SI (1) | SI1335908T1 (en) |
| SK (1) | SK5412003A3 (en) |
| SV (1) | SV2003000727A (en) |
| TW (1) | TW200716572A (en) |
| UA (1) | UA82048C2 (en) |
| WO (1) | WO2002038553A2 (en) |
| ZA (1) | ZA200302517B (en) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7205321B2 (en) | 2001-11-15 | 2007-04-17 | Eli Lilly And Company | Peroxisome proliferator activated receptor alpha agonists |
| GB0314079D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| JP2005529975A (en) | 2002-06-19 | 2005-10-06 | イーライ・リリー・アンド・カンパニー | Amide linker peroxisome proliferator activated receptor modulator |
| TW200505441A (en) | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
| FR2866339B1 (en) * | 2004-02-18 | 2006-05-05 | Pf Medicament | 1,2,4-TRIAZINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS |
| US7262318B2 (en) | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| KR100803481B1 (en) * | 2004-07-27 | 2008-02-14 | 에프. 호프만-라 로슈 아게 | Benzyltriazolone Compounds as Non-Nucleoside Reverse Transcriptase Inhibitors |
| US8293778B2 (en) | 2004-07-27 | 2012-10-23 | Roche Palo Alto Llc | Heterocyclic antiviral compounds |
| BRPI0513858B8 (en) * | 2004-07-27 | 2021-05-25 | Hoffmann La Roche | benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors, their preparation process, their use and pharmaceutical composition comprising them |
| AU2005272389B2 (en) * | 2004-08-11 | 2011-08-04 | Kyorin Pharmaceutical Co., Ltd. | Novel cyclic aminobenzoic acid derivative |
| WO2006068199A1 (en) * | 2004-12-22 | 2006-06-29 | Mochida Pharmaceutical Co., Ltd. | Metabolically stable 3-oxy-1,2,4-triazole derivatives |
| DOP2006000018A (en) * | 2005-01-28 | 2006-07-15 | Lilly Co Eli | FORMULATIONS AND DOSAGE REGIME FOR ALFA PPAR MODULATORS |
| FR2882750B1 (en) * | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | 1,2,4-TRIAZINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS |
| JPWO2006101108A1 (en) * | 2005-03-23 | 2008-09-04 | 杏林製薬株式会社 | Novel cyclic aminophenylalkanoic acid derivatives |
| CN101180280A (en) * | 2005-03-24 | 2008-05-14 | 弗·哈夫曼-拉罗切有限公司 | 1,2, 4-triazol-5-one compounds as heterocyclic reverse transcriptase inhibitors |
| JP5225076B2 (en) * | 2006-04-27 | 2013-07-03 | 田辺三菱製薬株式会社 | Pharmaceutical use of carboxylic acid derivatives containing thiazole ring |
| EA200970793A1 (en) * | 2007-02-23 | 2010-02-26 | Эли Лилли Энд Компани | MODULATORS OF RECEPTORS ACTIVATED BY PROLIFERATORS PEROXIS |
| WO2008119662A1 (en) | 2007-03-29 | 2008-10-09 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
| WO2010002712A2 (en) * | 2008-06-30 | 2010-01-07 | 3M Innovative Properties Company | Method of crystallization |
| CN101643451B (en) * | 2008-08-07 | 2013-03-06 | 浙江海正药业股份有限公司 | Peroxisome proliferator-activated receptor subtype delta agonist compound and preparation method thereof |
| TW201022221A (en) | 2008-12-01 | 2010-06-16 | Mitsubishi Tanabe Pharma Corp | Carboxylic acid derivatives containing thiazole ring and pharmaceutical use thereof |
| US20110167512A1 (en) * | 2009-03-02 | 2011-07-07 | Nunhems B.V. | Hybrid artichoke variety nun 4006 ar |
| US8575430B2 (en) * | 2010-03-02 | 2013-11-05 | Nunhems, B.V. | Hybrid artichoke variety NUN 4006 AR |
| DE102010001064A1 (en) * | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and their use |
| US20100245582A1 (en) * | 2009-03-25 | 2010-09-30 | Syclipse Technologies, Inc. | System and method of remote surveillance and applications therefor |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US8648233B2 (en) * | 2010-09-20 | 2014-02-11 | Nunhems B.V. | Hybrid artichoke variety NUN 4021 AR |
| US8669420B2 (en) | 2012-02-29 | 2014-03-11 | Nunhems B.V. | Hybrid artichoke variety NUN 4060 AR |
| EP2822931B1 (en) * | 2012-03-09 | 2017-05-03 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| SG11201504622PA (en) | 2012-12-20 | 2015-07-30 | Inception 2 Inc | Triazolone compounds and uses thereof |
| CN105579440A (en) * | 2013-09-06 | 2016-05-11 | 因森普深2公司 | Triazolone compounds and uses thereof |
| RU177130U1 (en) * | 2017-11-29 | 2018-02-09 | Владимир Алексеевич Коннов | INSULATING FACING PLATE |
| CN115398657A (en) | 2020-04-10 | 2022-11-25 | 松下知识产权经营株式会社 | Thermoelectric conversion element, thermoelectric conversion module, bonding material, and method for manufacturing thermoelectric conversion element |
| CN112774869B (en) * | 2020-12-25 | 2022-09-16 | 厦门紫金矿冶技术有限公司 | Pyrite inhibitor, preparation thereof and application thereof in copper-lead-zinc multi-metal sulfide ores |
| CN114853686B (en) * | 2021-08-23 | 2023-06-20 | 中国药科大学 | Triazolone compounds and their medicinal uses |
| CN115894379B (en) * | 2022-01-20 | 2025-06-27 | 哈尔滨三联药业股份有限公司 | Hydantoin compound and medical application thereof |
| CN114563394B (en) * | 2022-02-10 | 2025-03-11 | 湖南东方钪业股份有限公司 | A method for detecting impurity content in scandium fluoride |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2090283A1 (en) * | 1992-02-28 | 1993-08-29 | Nobuyuki Hamanaka | Phenoxyacetic acid derivatives |
| US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
| DE19517505A1 (en) * | 1995-05-12 | 1996-11-14 | Bayer Ag | Sulfonylamino (thio) carbonyltriazolin (thi) ones with aryloxy or arylthio substituents |
| JPH11513382A (en) * | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 5-membered heterocyclic compounds, pharmaceuticals containing these compounds, their use and methods for their preparation |
| ATE266639T1 (en) * | 1997-10-17 | 2004-05-15 | Yamanouchi Pharma Co Ltd | AMIDE DERIVATIVES OR SALTS THEREOF |
| EP1073643B1 (en) * | 1998-04-23 | 2004-12-29 | Dr. Reddy's Laboratories Ltd. | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| PE20011010A1 (en) | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | OXAZOLES AND THIAZOLES REPLACED AS AGONIST OF THE RECEPTOR ACTIVATED BY THE HUMAN PEROXISOMAS PROLIFERATOR |
| US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| USPP14578P2 (en) * | 2002-09-23 | 2004-03-09 | Plant Sciences, Inc. | Artichoke plant named ‘PS-MSC0003’ |
-
2001
- 2001-09-11 UA UA2003054187A patent/UA82048C2/en unknown
- 2001-11-07 AR ARP010105214A patent/AR031305A1/en unknown
- 2001-11-08 TW TW095138799A patent/TW200716572A/en unknown
- 2001-11-08 MY MYPI20015155A patent/MY157884A/en unknown
- 2001-11-08 PE PE2001001108A patent/PE20020693A1/en not_active Application Discontinuation
- 2001-11-09 CZ CZ20031283A patent/CZ20031283A3/en unknown
- 2001-11-09 WO PCT/US2001/042928 patent/WO2002038553A2/en not_active Ceased
- 2001-11-09 KR KR1020037006301A patent/KR100839705B1/en not_active Expired - Fee Related
- 2001-11-09 NZ NZ524569A patent/NZ524569A/en unknown
- 2001-11-09 HU HU0301655A patent/HUP0301655A2/en unknown
- 2001-11-09 SV SV2001000727A patent/SV2003000727A/en not_active Application Discontinuation
- 2001-11-09 CA CA002421154A patent/CA2421154A1/en not_active Abandoned
- 2001-11-09 BR BR0114986-5A patent/BR0114986A/en not_active IP Right Cessation
- 2001-11-09 DE DE60132799T patent/DE60132799T2/en not_active Expired - Fee Related
- 2001-11-09 AT AT01989704T patent/ATE386026T1/en not_active IP Right Cessation
- 2001-11-09 EP EP01989704A patent/EP1335908B1/en not_active Expired - Lifetime
- 2001-11-09 CN CNA018185878A patent/CN1479728A/en active Pending
- 2001-11-09 SK SK541-2003A patent/SK5412003A3/en not_active Application Discontinuation
- 2001-11-09 HR HR20030365A patent/HRP20030365A2/en not_active Application Discontinuation
- 2001-11-09 DK DK01989704T patent/DK1335908T3/en active
- 2001-11-09 IL IL15484001A patent/IL154840A0/en unknown
- 2001-11-09 ES ES01989704T patent/ES2300378T3/en not_active Expired - Lifetime
- 2001-11-09 JP JP2002541088A patent/JP4243101B2/en not_active Expired - Fee Related
- 2001-11-09 SI SI200130828T patent/SI1335908T1/en unknown
- 2001-11-09 US US10/415,673 patent/US7304062B2/en not_active Expired - Fee Related
- 2001-11-09 EA EA200300558A patent/EA006920B1/en not_active IP Right Cessation
- 2001-11-09 MX MXPA03004141A patent/MXPA03004141A/en active IP Right Grant
- 2001-11-09 AU AU2002228592A patent/AU2002228592B8/en not_active Ceased
- 2001-11-09 AU AU2859202A patent/AU2859202A/en active Pending
- 2001-11-09 PL PL01362692A patent/PL362692A1/en unknown
- 2001-11-09 PT PT01989704T patent/PT1335908E/en unknown
-
2003
- 2003-03-10 IL IL154840A patent/IL154840A/en active IP Right Grant
- 2003-03-31 ZA ZA200302517A patent/ZA200302517B/en unknown
- 2003-05-08 EC EC2003004595A patent/ECSP034595A/en unknown
- 2003-05-08 NO NO20032059A patent/NO20032059L/en unknown
-
2006
- 2006-06-29 AU AU2006202811A patent/AU2006202811A1/en not_active Abandoned
-
2007
- 2007-07-26 US US11/828,446 patent/US20090062358A1/en not_active Abandoned
-
2008
- 2008-04-10 CY CY20081100391T patent/CY1107388T1/en unknown
- 2008-06-27 US US12/215,466 patent/US7868225B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP034595A (en) | ALFA ACTIVATED RECEPTOR AGONIST OF THE PEROXISOM PROLIFER | |
| PE20221083A1 (en) | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND THEIR METHODS OF USE | |
| AR034405A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING DERIVATIVES OF 3-AMINO-AZETIDINE, THE NEW DERIVATIVES AND THEIR PREPARATION | |
| PE20020190A1 (en) | HETEROCYCLIC CARBOXAMIDES AS ANTIVIRAL AGENTS | |
| AR041867A1 (en) | AGENT TO PREVENT OR TREAT NEUROPATHY | |
| PE20040451A1 (en) | SUBSTITUTE CYCLOALKYL ACTIVATORS AND OXYGENATED CYCLOALKYL OF GLUCOKINASE | |
| ES2571327T3 (en) | Pesticide Compositions | |
| AR048055A1 (en) | PIRIMIDINE DERIVATIVES AS INHIBITORS OF DIPEPTIDIL PEPTIDASA | |
| PE20001317A1 (en) | N- (SUBSTITUTED GLYCYL) -2-CYANOPYRROLIDINES AS DPP-IV INHIBITORS | |
| CO5450245A1 (en) | CHEMICAL COMPOUNDS WITH DOUBLE ACTIVITY, PROCEDURES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS | |
| CO5640155A2 (en) | PIRIDO DERIVATIVES [2,1-A] ISOQUINOLINE AS INHIBITORS OF DPP-IV | |
| BR112012007069A2 (en) | phenol derivative | |
| AR045782A2 (en) | PIPERIDINE DERIVATIVES THAT HAVE PHARMACEUTICAL ACTIVITY | |
| CO5721002A2 (en) | ACID DERIVATIVES 3- (4-BENCILOXIFENIL) PROPANOIC | |
| PE20060427A1 (en) | PIRAZOLE DERIVATIVES AS GLUCAGON BINDING INHIBITORS AND COMPOSITIONS | |
| PE20080843A1 (en) | RENIN INHIBITORS AND METHOD FOR THEIR USE | |
| UY26820A1 (en) | DERIVATIVES OF CYCLOPENTIL-GLUTARAMIDE AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | |
| ECSP066695A (en) | DERIVATIVES OF N- (1,5-DIFENIL-1H-PIRAZOL-3-IL) SULFONAMIDE AFFECTED BY CB1 RECEPTORS | |
| AR065850A1 (en) | SOLID PHARMACEUTICAL COMPOSITION INCLUDING A BENZIMIDAZOL-7-CARBOXYLATE DERIVATIVE AND A PH CONTROL AGENT | |
| ES2531149T3 (en) | 2-Pyridinylethylcarboxamide derivatives and their use as fungicides | |
| CO6251235A2 (en) | COMPOUNDS DERIVED FROM AZETIDINES ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
| UY29388A1 (en) | DERIVATIVES OF (1,5-DIFENIL-H-PIRAZOL-3-IL) OXADIAZOL, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS. | |
| CO4790128A1 (en) | SYNERGIC COMPOSITIONS CONTAINING PIRIDABEN, PHENOXPIRO-XAMATO, TEBUFENPIRAD AND AT LEAST ONE COMPOUND AMIDO, AND METHOD FOR CONTROLLING PHYTHODANINE FUNGI | |
| PE20060323A1 (en) | OXADIAZOLONES AND PROCEDURES FOR THEIR PREPARATION | |
| CO6160324A2 (en) | REPLACED HETEROCICLES CONTAINING NITROGEN AS INHIBITORS OF THE ADP PLAQUETARY RECEIVER |